Translation in two advanced BC patients, resulted in no side effects, confirming previous observations on the biosafety of radiotracers based on the potent GRPR-antagonist [DPhe6,LeuNHEt13]BBN(6-13) and on GRPR-antagonist radioligands in general. Here, GRPR is linked to breast cancer.